Antiepileptic drug use and rates of hip bone loss in older men: A prospective study

Neurology

Volumn 71, Issue 10, 2008, Pages 723-730

  Ensrud, K E ^a,b,h   Walczak, T S ^c,d   Blackwell, T L ^e   Ensrud, E R ^a   Barrett Connor, E ^f   Orwoll, E S ^g  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Division of Epidemiology and Community Health   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d Minnesota Comprehensive Epilepsy Program   (United States)

^e CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CARBAMAZEPINE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; SEROTONIN UPTAKE INHIBITOR; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VITAMIN D;

AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; BONE DENSITY; BONE PAIN; CALCIUM INTAKE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMMUNITY LIVING; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIABETES MELLITUS; DRUG USE; DUAL ENERGY X RAY ABSORPTIOMETRY; HEALTH STATUS; HIGH RISK POPULATION; HIP; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; PHYSICAL DISABILITY; PRIORITY JOURNAL; QUESTIONNAIRE; RACE; SEIZURE; SMOKING; VITAMIN SUPPLEMENTATION; CHEMICALLY INDUCED DISORDER; DEMOGRAPHY; DRUG EFFECT; EPILEPSY; GERIATRIC ASSESSMENT; METABOLIC BONE DISEASE; METHODOLOGY; OSTEOPOROSIS; PATHOLOGY; PHOTON ABSORPTIOMETRY; PHYSIOLOGY; RETROSPECTIVE STUDY;

ABSORPTIOMETRY, PHOTON; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; BONE DENSITY; BONE DISEASES, METABOLIC; COHORT STUDIES; EPILEPSY; GERIATRIC ASSESSMENT; HIP; HUMANS; MALE; OSTEOPOROSIS; QUESTIONNAIRES; RESIDENCE CHARACTERISTICS; RETROSPECTIVE STUDIES;

EID: 54049125779     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000324919.86696.a9     Document Type: Article

References (34)

1. Petty SJ, O'Brien TJ, Wark JD. Anti-epileptic medication and bone health. Osteoporos Int 2007;18:129-142.
2. Tannirandorn P, Epstein S. Drug-induced bone loss. Osteoporos Int 2000;11:637-659.
3. Sato Y, Kondo I, Ishida S, et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001;57:445-449.
4. Chung S, Ahn C. Effects of anti-epileptic drug therapy on bone mineral density in ambulatory epileptic children. Brain Dev 1994;16:382-385.
5. Kubota F, Kifune A, Shibata N, et al. Bone mineral density of epileptic patients on long-term antiepileptic drug therapy: a quantitative digital radiography study. Epilepsy Res 1999;33:93-97.
6. Valimaki MJ, Tiihonen M, Laitinen K, et al. Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J Bone Miner Res 1994;9: 631-637.
7. Pack AM, Morrell MJ, Marcus R, et al. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol 2005;57:252-257.
8. Sheth RD, Wesolowski CA, Jacob JC, et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr 1995;127:256-262.
9. Kafali G, Erselcan T, Tanzer F. Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years. Clin Pediatr (Phila) 1999;38:93-98.
10. Kim SH, Lee JW, Choi KG, Chung HW, Lee HW. A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy. Epilepsy Behav 2007;10: 291-295.
11. Fitzpatrick LA. Pathophysiology of bone loss in patients receiving anticonvulsant therapy. Epilepsy Behav 2004;5 suppl 2:S3-15.
12. LaRoche SM, Helmers SL. The new antiepileptic drugs: clinical applications. JAMA 2004;291:615-620.
13. McCorry D, Chadwick D, Marson A. Current drug treatment of epilepsy in adults. Lancet Neurol 2004; 3:729-735.
14. Pack AM, Morrell MJ. Epilepsy and bone health in adults. Epilepsy Behav 2004;5 suppl 2:S24-S29.
15. Orwoll E, Blank JB, Barrett-Connor E, et al. Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study-a large observational study of the determinants of fracture in older men. Contemp Clin Trials 2005; 26:569-585.
16. Blank JB, Cawthon PM, Carrion-Petersen ML, et al. Overview of recruitment for the osteoporotic fractures in men study (MrOS). Contemp Clin Trials 2005;26:557-568.
17. Pahor M, Chrischilles EA, Guralnik JM, Brown SL, Wallace RB, Carbonin P. Drug data coding and analysis in epidemiologic studies. Eur J Epidemiol 1994;10:405-411.
18. Washburn RA, Ficker JL. Physical Activity Scale for the Elderly (PASE): the relationship with activity measured by a portable accelerometer. J Sports Med Phys Fitness 1999; 39:336-340.
19. Block G, Subar AF. Estimates of nutrient intake from a food frequency questionnaire: the 1987 National Health Interview Survey. J Am Diet Assoc 1992;92:969-977.
20. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127(8 Pt 2):757-763.
21. Andress DL, Ozuna J, Tirschwell D, et al. Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch Neurol 2002;59:781-786.
22. Ensrud KE, Walczak TS, Blackwell T, Ensrud ER, Bowman PJ, Stone KL. Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology 2004;62:2051-2057.
23. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia 2004;45: 1330-1337.
24. Souverein PC, Webb DJ, Weil JG, Van Staa TP, Egberts AC. Use of antiepileptic drugs and risk of fractures: casecontrol study among patients with epilepsy. Neurology 2006;66:1318-1324.
25. Feldkamp J, Becker A, Witte OW, Scharff D, Scherbaum WA. Long-term anticonvulsant therapy leads to low bone mineral density: evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp Clin Endocrinol Diabetes 2000;108:37-43.
26. Cho HH, Park HT, Kim YJ, Bae YC, Suh KT, Jung JS. Induction of osteogenic differentiation of human mesenchymal stem cells by histone deacetylase inhibitors. J Cell Biochem 2005;96:533-542.
27. Gracious BL, Bossert RP, Puza J. Valproic acid inhibits osteoblast and osteoclast activity in therapeutic dose ranges. J Bone Miner Res 2004;19(suppl 1):S440Abs.
28. Schroeder TM, Westendorf JJ. Histone deacetylase inhibitors promote osteoblast maturation. J Bone Miner Res 2005;20:2254-2263.
29. Nissen-Meyer LS, Svalheim S, Tauboll E, et al. Levetiracetam, phenytoin, and valproate act differently on rat bone mass, structure, and metabolism. Epilepsia 2007;48:1850-1860.
30. Hayashida K, DeGoes S, Curry R, Eisenach JC. Gabapentin activates spinal noradrenergic activity in rats and humans and reduces hypersensitivity after surgery. Anesthesiology 2007;106:557-562.
31. Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002;111:305-317.
32. Koch HU, Kraft D, von HD, Schaefer K. Influence of diphenylhydantoin and phenobarbital on intestinal calcium transport in the rat. Epilepsia 1972;13:829-834.
33. Elliott JO, Jacobson MP, Haneef Z. Homocysteine and bone loss in epilepsy. Seizure 2007;16:22-34.
34. Pack AM, Morrell MJ, Flynn KL, Done S. Possible mechanisms of bone disease in women receiving antiepileptic drug (AED) monotherapy. Epilepsia 2001;42:292.